TUKYSA ADDED TO FIRST-LINE MAINTENANCE THERAPY EXTENDS MEDIAN PROGRESSION-FREE SURVIVAL BY OVER 8 MONTHS IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER

Reuters · 2d ago

Please log in to view news